Bisoprolol in DMD Early Cardiomyopathy | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
recruiting

Bisoprolol in DMD Early Cardiomyopathy

key information

study id #: NCT03779646

condition: Duchenne Muscular Dystrophy, Cardiomyopathy, Dilated

status: recruiting

purpose:

This study aimed to use cardiac magnetic resonance imaging (CMR) to evaluate the efficacy and safety of bisoprolol therapy for boys with Duchenne muscular dystrophy (DMD) and preserved ejection fraction. On top of angiotensin-converting enzyme inhibitor (ACEI), half of the participants will receive bisoprolol in combination, while the other half will not receive any beta-blocker.

intervention: Bisoprolol Fumarate

mechanism of action: Beta-blocker to prevent cardiac function deterioration

results: https://clinicaltrials.gov/ct2/show/results/NCT03779646

last updated: February 04, 2019

study details

start date: January 16, 2019

estimated completion: July 1, 2020

phase of development: Phase 2/Phase 3

size / enrollment: 42

study description:
By the age of 20 years, almost all the patients with Duchenne muscular dystrophy(DMD) have experienced dilated cardiomyopathy (DCM), a condition that contributes significantly to their morbidity and mortality. Studies have shown ACEI to be an effective therapy for DMD boys with early cardiomyopathy. Although bisoprolol has been demonstrated as an effective neurohumoral drug for adult patients with DCM, few data exist concerning its safety and efficacy for the patients with DMD. The investigators hypothesize that the treatment with bisoprolol in addition to background ACEI therapy for 12 months in participants with DMD and early myocardial damage evident with late gadolinium enhancement and preserved ejection fraction would blunt decline in left ventricular systolic performance.

primary outcomes:

  • Calculate the change of left ventricle global longitudinal strain in cardiac MR [ Time Frame: baseline and 12 months ]
    Calculate the change of left ventricle global longitudinal strain in cardiac MR from baseline to 12months for each patients

secondary outcomes:

  • Calculate the change of left ventricular ejection fraction in cardia MR [ Time Frame: baseline and 12 months ]
    Calculate the change of left ventricular ejection fraction in cardia MR from baseline to 12months for each patients
  • Calculate the change of ventricle late gadolinium enhancement area in cardia MR [ Time Frame: baseline and 12 months ]
    Calculate the change of ventricle late gadolinium enhancement area in cardia MR from baseline to 12months for each patients
  • Calculate the change of the level of high-sensitivity cardiac troponin I [ Time Frame: baseline and 6months, 12 months ]
    Calculate the change of the level of high-sensitivity cardiac troponin I from baseline to 6months and 12months for each patients
  • Calculate the change of the level of NT-proBNP [ Time Frame: baseline and 6months, 12 months ]
    Calculate the change of the level of NT-proBNP from baseline to 6months and 12months for each patients
  • Calculate the change of E/A ratio assessed by echocardiography [ Time Frame: baseline and 12 months ]
    Calculate the change of diastolic dysfunction (E/A ratio) assessed by echocardiography from baseline to 12months for each patients
  • Change of the resting heart rate [ Time Frame: baseline and 6months, 12 months ]
    Calculate the change of the resting heart rate from baseline to 6months and 12months for each patients

inclusion criteria:
• Older than (including) 7 years old
• A definite diagnosis of DMD with muscle pathology confirming the expression of dystrophin lower than 5% and/or confirmed mutations in the DMD gene using a clinical accepted technique that completely defines the mutation.
• Using ACEI or ARB for more than 1 month
• Confirmed myocardial damage in one or more left ventricular segments evident by late gadolinium enhancement and preserved left ventricular systolic function(>45%) by cine cardiac MR in 45 days
• Normal renal function
• Holter and blood pressure shows no contraindication of using bisoprolol

exclusion criteria:
• Having metal implanted in body
• Having claustrophobia
• Allergic to gadolinium
• Complicated with other cardiovascular diseases
• Medical history or Holter show bradyarrhythmia like II/III degree atrioventricular block, sick sinus syndrome etc.
• Systolic blood pressure lower than 90mmHg or rest heart rate lower than 75bpm
• Having COPD or asthma history
• Having other complications: tumor, endocrine diseases
• Having beta blockers therapy
• Planned operation in the future 12 months
• Allergic to bisoprolol

study contacts

sponsor: Peking Union Medical College Hospital

contacts: Guo Doctor, +86-010-69155068, xiaoxiaoguopumch@163.com

locations: China